| Second-line Chemotherapy with Paclitaxel and Carboplatin for Patients with Recurrent Ovarian Carcinoma. |
|
Hyung Joo Seo, Chul Min Lee, Jaung Sun Kim, Hye Joo Lee, Yong Joo Park, Yong Kyoon Cho, Hoon Choi, Bok Rin Kim, Hong Kyoon Lee |
|
Department of Obstetrics and Gynecology, Inje University, Sanggye Paik Hospital, Seoul, Korea. |
|
|
| Abstract |
OBJECTIVE
This study is to investigate the efficacy and toxicity of paclitaxel plus carboplatin used as a salvage therapy. METHODS: Between June 2000 and November 2003, 10 patients aged 43-74 (median 55.0) with recurrent ovarian carcinoma were given combination chemotherapy including paclitaxel and carboplatin. The subjects received initial chemotherapy with paclitaxel plus cisplatin/carboplatin. On recurrence, paclitaxel was administered intravenously at a dose of 175 mg/m2 with carboplatin by AUC 5 every 3 weeks. The median treatment cycle was 10 cycles (range, 1 to 15 cycles). Recurrence of ovarian carcinoma was determined by elevation of serum CA-125, or radiologic imaging. Responses and toxicities were evaluated according to Gynecologic Oncology Group criteria and Common Terminology Criteria for Adverse Events from NCI (National Cancer Institute). RESULTS: The overall clinical response rate was 60.0% (6/10). Better response was observed in patients who were sensitive with initial chemotherapy. Anemia was the most frequent complication. CONCLUSION: Paclitaxel and carboplatin has been shown to be a feasible agent in patients with recurrent ovarian cancer. |
| Key Words:
Paclitaxel, Salvage therapy, Recurrent ovarian carcinoma |
|
Full text via DOI
Download Citation
